Phase II study of autologous stem cell transplant using busulfanmelphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma

Andrew Grigg, Janey Stone, Alvin Milner, Anthony Schwarer, Max Wolf, Miles Prince, John Seymour, Devinder Gill, David Ellis, John Bashford

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


Alpha interferon has proven efficacy in prolonging remissions in patients with follicular non-Hodgkin lymphoma (NHL) when given concurrently with or after conventional-dose anthracycline-based chemotherapy, but there are limited data on its use after myeloablative conditioning. We prospectively evaluated the toxicity and efficacy of interferon given thrice weekly for up to 5 years post-engraftment in patients with relapsed follicular NHL undergoing autologous stem cell transplant using busulfan-melphalan conditioning. Thirty-seven patients were enrolled in this Australasian Leukaemia Lymphoma Group study and transplanted between 1995 and 1999. Only one patient had received prior rituximab. Two patients died of transplant-related toxicity; 28 of the remainder commenced interferon, but it was discontinued prematurely in most patients due to toxicity (mainly fatigue and depression) or relapse. While the majority of patients (29/36 evaluable: 81 ) achieved a complete remission based on clinical and CT scan criteria post-transplant, most relapsed relatively early, with a median progression-free survival of 2.4 years. The overall survival at 7 years was 49 . Eight patients (22 ), however, remain alive a median of 9.3 years post-transplant, having never relapsed, and another six patients (16 ) remain alive in durable remission after salvage therapy. These results demonstrate that interferon is poorly tolerated post-autograft and hence is unlikely to positively contribute to patient outcome. Long-term follow-up demonstrates that autografting may result in durable remissions in a meaningful minority of patients with relapsed follicular NHL.
Original languageEnglish
Pages (from-to)641 - 649
Number of pages9
JournalLeukemia and Lymphoma
Issue number4
Publication statusPublished - 2010
Externally publishedYes

Cite this